Want to see HK:2096 full AI Analyst Report?
2096 Stock Chart & Stats
HK$13.79
-HK$0.02(-0.30%)
At close: 4:00 PM EST
HK$13.79
-HK$0.02(-0.30%)
Day’s Range― - ―
52-Week RangeHK$9.07 - HK$15.08
Previous CloseN/A
Volume1.11M
Average Volume (3M)9.82M
Market Cap
HK$31.72B
Enterprise ValueHK$18.54B
Total Cash (Recent Filing)HK$3.62B
Total Debt (Recent Filing)HK$1.20B
Price to Earnings (P/E)20.0
Beta0.68
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.68%
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,568,198,700
10 Day Avg. Volume8,933,647
30 Day Avg. Volume9,821,905
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)2.84
Price to Sales (P/S)3.46
P/FCF Ratio23.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$19.21Price Target Upside39.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginAn ~82% gross margin is a durable structural advantage in pharmaceuticals: it supports sustained internal cash generation and funds R&D and clinical programs. Such margin levels indicate pricing power for branded drugs and provide a long-term cushion versus reimbursement or cost shocks.
Revenue Re-accelerationRevenue re-acceleration in 2025 (up 8.8%) atop multi-year expansion signals improving commercial execution and product adoption in core therapeutic areas. A steady top-line trend supports scalable SG&A absorption, sustained investment in launches, and longer-term market-share gains.
Conservative Balance SheetDebt-to-equity down to ~0.13 and materially higher equity reflect conservative financing and improving ROE (~14.3%). Low leverage provides financial flexibility to fund clinical programs, pursue licensing/partnerships, and withstand pricing or reimbursement cycles without forced deleveraging.
Bears Say
Inconsistent Free Cash FlowIntermittent negative free cash flow years and uneven cash conversion reduce predictability of internally funded R&D, dividends, or M&A. Despite improved 2025 OCF and positive FCF, the historical volatility implies potential reliance on external funding in adverse periods.
Earnings / Margin VolatilityLarge swings in net margin (≈30% in 2021 to ~11% in 2024, then ~17.4% in 2025) point to volatile earnings quality driven by mix, one-offs, or pricing dynamics. This variability undermines forward earnings visibility and complicates sustainable cash-flow and capital-allocation planning.
Meaningful Absolute DebtAlthough leverage ratios are low, ~1.20B of absolute debt requires servicing. Given prior FCF volatility, fixed obligations could constrain discretionary spending for launches, partnerships, or acquisitions and reduce agility during slower revenue periods.
Simcere Pharmaceutical Group Limited News
2096 FAQ
What was Simcere Pharmaceutical Group Limited’s price range in the past 12 months?
Simcere Pharmaceutical Group Limited lowest stock price was HK$9.07 and its highest was HK$15.08 in the past 12 months.
What is Simcere Pharmaceutical Group Limited’s market cap?
Simcere Pharmaceutical Group Limited’s market cap is HK$31.72B.
When is Simcere Pharmaceutical Group Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Simcere Pharmaceutical Group Limited’s earnings last quarter?
Currently, no data Available
Is Simcere Pharmaceutical Group Limited overvalued?
According to Wall Street analysts Simcere Pharmaceutical Group Limited’s price is currently Undervalued.
Does Simcere Pharmaceutical Group Limited pay dividends?
Simcere Pharmaceutical Group Limited pays a Annually dividend of HK$0.207 which represents an annual dividend yield of 1.68%. See more information on Simcere Pharmaceutical Group Limited dividends here
What is Simcere Pharmaceutical Group Limited’s EPS estimate?
Simcere Pharmaceutical Group Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Simcere Pharmaceutical Group Limited have?
Simcere Pharmaceutical Group Limited has 2,568,198,700 shares outstanding.
What happened to Simcere Pharmaceutical Group Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Simcere Pharmaceutical Group Limited?
Currently, no hedge funds are holding shares in HK:2096
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Simcere Pharmaceutical Group Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$19.21 (39.28% Upside)
HK$19.21 (39.28% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
109.73%
12-Months-Change
Fundamentals
Return on Equity
1.68%
Trailing 12-Months
Asset Growth
33.90%
Trailing 12-Months
Company Description
Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Limited is a Chinese entity engaged in the comprehensive process of discovering, developing, manufacturing, and commercializing pharmaceutical products. These medicines are distributed to various clients, including distributors, pharmacy chains, and fellow drug manufacturers within China. The company strategically focuses on a diverse range of therapeutic areas, notably oncology, central nervous system conditions, autoimmune diseases, anti-infective treatments, and cardiovascular health, among others. Its extensive product portfolio features key medications such as Sanbexin (an edaravone and dexborneol concentrated solution for injection), Endostar (a recombinant human endostatin injection), ENWEIDA (an envafolimab injection), Softan (rosuvastatin calcium tablets), ZAILIN (amoxicillin in granules, dispersible tablets, or capsules), Iremod (iguratimod tablets), Antine (diclofenac sodium sustained-release capsules or gel), and Orencia (an abatacept injection). Additionally, Simcere offers specialized promotional services for pharmaceutical goods. Demonstrating its commitment to innovation, the group has established a strategic regional licensing collaboration with Vivoryon Therapeutics N.V. This partnership aims to develop and commercialize novel therapies for Alzheimer's disease by targeting the neurotoxic amyloid protein N3pE (pGlu-Aß). Established in 1995, Simcere Pharmaceutical Group Limited is headquartered in Nanjing, China.
2096 Stock 12 Month Forecast
Average Price Target
HK$19.21
▲(39.28% Upside)
Technical Analysis
Zai Lab Ltd
―
InnoCare Pharma Ltd.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
CStone Pharmaceuticals
―
Shanghai Henlius Biotech, Inc. Class H
―